Mortality rates not increased in pregnancy-associated malignant melanoma

This article originally appeared here.
Share this content:
Mortality rates not increased in pregnancy-associated malignant melanoma
Mortality rates not increased in pregnancy-associated malignant melanoma

(HealthDay News) -- Cause-specific mortality does not differ significantly for women and girls with malignant melanoma (MM) diagnosed during pregnancy and up to two years postpartum (pregnancy-associated MM [PAMM]) and with non-PAMM, according to a study published in the December issue of the Journal of the American Academy of Dermatology.

Anna L.V. Johansson, from the Karolinska Institutet in Stockholm, and colleagues examined mortality in women with PAMM in a population-based cohort study. Data were obtained from the Swedish Cancer and Multi-Generation Registers.

From 1963 to 2009, the researchers identified 6,857 women and girls aged 15 to 44 years with a diagnosis of cutaneous MM. Overall, 1,019 cases were categorized as PAMM. There was no significant difference in the cause-specific mortality between PAMM and MM not diagnosed near childbirth (adjusted hazard ratio, 1.09; 95 percent confidence interval, 0.83 to 1.42).

"Given the findings of the current study, and the inconsistent results in earlier studies, we conclude that there is no compelling support for an overall detrimental effect of pregnancy on the prognosis of MM," the authors write.

Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs